RPG Life Sciences has partnered with Archerchem Healthcare to introduce Naprosyn ES, a new combination of Naproxen and Esomeprazole, in the Indian market. The product marks the first launch of this combination in the country and is aimed at providing effective pain relief while helping protect the stomach during long-term treatment.
Naprosyn ES combines the anti-inflammatory benefits of Naproxen with the stomach-protective properties of Esomeprazole. The formulation has been jointly developed by Archerchem Healthcare and its development partner to address the needs of patients who require prolonged treatment with nonsteroidal anti-inflammatory drugs (NSAIDs).
Under the agreement, RPG Life Sciences will have exclusive rights to market and distribute Naprosyn ES across India, while Archerchem Healthcare will remain the exclusive supplier of the product. The new medicine is designed for patients who need long-term pain management and are at risk of stomach-related side effects commonly associated with NSAID therapy. By combining pain relief with gastroprotection in a single tablet, the product is expected to improve treatment adherence and support safer long-term use, particularly among elderly patients and those with sensitive digestive systems.
Ashok Nair, Managing Director of RPG Life Sciences, said the launch reflects the company’s focus on developing patient-focused products that meet evolving healthcare needs. He added that the trusted Naprosyn brand has earned the confidence of doctors and patients over the years, and Naprosyn ES further strengthens the company’s portfolio in pain management.
Anil Dhedi, Chairman and Managing Director of Archerchem Healthcare, said the partnership highlights the company’s expertise in developing advanced pharmaceutical formulations. He noted that working with RPG Life Sciences will help make the new treatment available to patients across the country while supporting better treatment outcomes through improved medication adherence.
RPG Life Sciences plans to build on the strong recognition of the Naprosyn brand and use its extensive sales network and nationwide distribution system to make the product widely available. The company also has a strong presence among physicians, specialists, and healthcare professionals across India, which is expected to support the product’s reach.
The launch is in line with RPG Life Sciences’ strategy to expand its portfolio of differentiated products in chronic therapy segments. The company operates across branded formulations, global generics, and active pharmaceutical ingredients, serving both domestic and international markets.
Archerchem Healthcare is an Indian pharmaceutical company with operations in global markets. The company focuses on developing affordable generic medicines and complex formulations that improve patient care across a wide range of therapeutic areas.
